Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.

Parham DM, Qualman SJ, Teot L, Barr FG, Morotti R, Sorensen PH, Triche TJ, Meyer WH; Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Am J Surg Pathol. 2007 Jun;31(6):895-901.

PMID:
17527077
2.
3.

Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell?

Charytonowicz E, Cordon-Cardo C, Matushansky I, Ziman M.

Cancer Lett. 2009 Jul 8;279(2):126-36. doi: 10.1016/j.canlet.2008.09.039. Epub 2008 Nov 12. Review.

PMID:
19008039
4.

Classification of rhabdomyosarcoma and its molecular basis.

Parham DM, Barr FG.

Adv Anat Pathol. 2013 Nov;20(6):387-97. doi: 10.1097/PAP.0b013e3182a92d0d. Review.

PMID:
24113309
5.

New genetic tactics to model alveolar rhabdomyosarcoma in the mouse.

Keller C, Capecchi MR.

Cancer Res. 2005 Sep 1;65(17):7530-2. Review.

6.
7.

Molecular biology of rhabdomyosarcoma.

Gallego Melcón S, Sánchez de Toledo Codina J.

Clin Transl Oncol. 2007 Jul;9(7):415-9. Review.

PMID:
17652054
8.

Fusions involving paired box and fork head family transcription factors in the pediatric cancer alveolar rhabdomyosarcoma.

Barr FG.

Curr Top Microbiol Immunol. 1997;220:113-29. Review. No abstract available.

PMID:
9103678
9.

Prognostic value of PAX3/7-FOXO1 fusion status in alveolar rhabdomyosarcoma: Systematic review and meta-analysis.

Kubo T, Shimose S, Fujimori J, Furuta T, Ochi M.

Crit Rev Oncol Hematol. 2015 Oct;96(1):46-53. doi: 10.1016/j.critrevonc.2015.04.012. Epub 2015 May 14. Review.

PMID:
26008753
10.

Molecular pathogenesis of rhabdomyosarcoma.

Xia SJ, Pressey JG, Barr FG.

Cancer Biol Ther. 2002 Mar-Apr;1(2):97-104. Review.

PMID:
12170781
11.

PAX3-FOXO1 fusion gene in rhabdomyosarcoma.

Linardic CM.

Cancer Lett. 2008 Oct 18;270(1):10-8. doi: 10.1016/j.canlet.2008.03.035. Epub 2008 May 23. Review.

12.

[Alveolar rhabdomyosarcoma of unknown origin mimicking acute leukemia at the initial presentation].

Yamaguchi K, Koga Y, Suminoe A, Saito Y, Matsuzaki A, Kanno S, Takimoto T, Suda M, Oda Y, Muto T, Takatsuki H, Hara T.

Rinsho Ketsueki. 2007 Apr;48(4):315-20. Review. Japanese.

PMID:
17515123
13.

A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma.

Olanich ME, Barr FG.

Expert Opin Ther Targets. 2013 May;17(5):607-23. doi: 10.1517/14728222.2013.772136. Epub 2013 Feb 25. Review.

PMID:
23432728
14.

PAX3-FKHR chimeric oncoprotein: hiding itself from immune detection?

Anderson J, Himoudi N.

Cell Cycle. 2006 Mar;5(6):563-4. Epub 2006 Mar 15. Review. No abstract available.

PMID:
16481750
15.

The inconvenience of convenience cohorts: rhabdomyosarcoma and the PAX-FOXO1 biomarker.

Rosenberg AR, Skapek SX, Hawkins DS.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1012-8. doi: 10.1158/1055-9965.EPI-12-0207. Epub 2012 May 7. Review.

16.

Uncovering metabolism in rhabdomyosarcoma.

Monti E, Fanzani A.

Cell Cycle. 2016;15(2):184-95. doi: 10.1080/15384101.2015.1071746. Review.

17.

Rhabdomyosarcoma: Advances in Molecular and Cellular Biology.

Sun X, Guo W, Shen JK, Mankin HJ, Hornicek FJ, Duan Z.

Sarcoma. 2015;2015:232010. doi: 10.1155/2015/232010. Epub 2015 Sep 1. Review.

Supplemental Content

Support Center